

# MISSISSIPPI DIVISION OF MEDICAID

## Pharmacy & Therapeutics Committee

### Table 100 / Flowood, MS

May 13, 2025

10:00am to 2:00pm

## AGENDA

- I. Call to Order
- II. Welcome & Introductions
- III. Administrative Matters
- IV. Approval of February 18, 2025 Meeting Minutes
- V. PDL Compliance/Generic Percent Report Updates
- VI. Public Comment
- VII. New Drug/New Generic Reviews
  1. **Anticoagulants (Oral):** rivaroxaban - *Financial Review Only*
  2. **Cystic Fibrosis Agents:** Alyftrek (vanzacaftor/tezacaftor/deutivacaftor)
  3. **Cytokine & CAM Antagonists:**  
Otulfi (ustekinumab-aauz) – *Financial Review Only*  
Pyzchiva (ustekinumab-ttwe) – *Financial Review Only*  
Yesintek (ustekinumab-kfce) – *Financial Review Only*  
Idacio (adalimumab-aacf) – *Financial Review Only*
  4. **Factor Deficiency Products (Other Hemophilia Products):**  
Alhemo (concizumab-mtci)  
Corifact (Factor XIII)
  5. **Fibromyalgia/Neuropathic Pain Agents:** Gabarone (gabapentin) – *Financial Review Only*
  6. **Irritable Bowel Syndrome/Short Bowel Syndrome Agents/Selected Agents (Constipation):** prucalopride – *Financial Review Only*
  7. **Miscellaneous Brand/Generic (Epinephrine):** Neffy (epinephrine) – *Financial Review Only*
  8. **Miscellaneous Brand/Generic (Miscellaneous):**  
Crenessity (crinecerfont)  
Tryngolza (olezarsen)
  9. **Select Contraceptives (Oral Contraceptives):**  
Xarah FE (Ethinyl estradiol and norethindrone acetate) – *Financial Review Only*  
Valtya (Ethinyl estradiol and ethynodiol diacetate) – *Financial Review Only*  
Feirza (Ethinyl estradiol and norethindrone acetate) – *Financial Review Only*
- VIII. Other Business
- IX. Division of Medicaid Update
- X. Remaining 2025 Meeting Dates
  1. Tuesday, August 12, 2025
  2. Tuesday, October 21, 2025